Eric Faulkner, Senior Director of US Market Access and Reimbursement, will Chair a session entitled Capturing the Value of Biomarkers: The Necessity of Planning from a Reimbursement Perspective at GTCBio’s Second Annual Rediscovering Biomarkers Conference to be held July 10-11 in Boston MA. The abstract for the session and other key speakers are as follows:
We are in the early days of an era where biomarkers are poised to redefine many aspects of health care practice and policy. More than virtually any other factor, reimbursement will play a pivotal role in the success of biomarker-based technologies. For rapidly evolving innovator diagnostics and treatments, it is clear that one-size-fits-all approaches are insufficient in an environment largely oriented towards characterizing the value of conventional treatments. What information are health decision makers looking for to characterize the value of biomarkers used in diagnostics and to inform treatment use or outcomes? What tools, metrics and processes are relevant and essential to pricing and reimbursement in the US? This session will explore current practice and policy issues associated with biomarkers in an environment increasingly focused on evidence-based and personalized health care, where reimbursement is a growing hurdle for new technology access and diffusion.
Distinguished speakers include the following:
- Laura Sullivan, Vice President, Reimbursement, Genzyme Genetics
- Bruce Quinn, Senior Health Policy Specialist, Foley Hoag LLP
- James Golubieski, President, Foundation Venture Capital Group, LLC
Mr. Faulkner’s responsibilities at RTI Health Solutions involve evaluation of US and international pricing and reimbursement issues, health technology assessment practices, product reimbursement and commercialization strategies and changing health policy. He has recently served as an expert advisor to the Personalized Medicine Subcommittee of the President’s Council of Advisors on Science and Technology and serves on the Leadership Committee of the Health Technology Assessment for Emerging Technologies Working Group of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
In addition to his role at RTI Health Solutions, Mr. Faulkner also serves as Director of the Genomic Biotech Institute (GBI) of the National Association of Managed Care Physicians (NAMCP) and is Editor-in-Chief of the GBI special section of the Journal of Managed Care Medicine, Genomics and Biotechnology.
Additional information about the conference is available here.
Please contact Eric directly if you plan to attend the conference and would like to pre-arrange a meeting time with him.